SMZL
MCID: SPL004
MIFTS: 44

Splenic Marginal Zone Lymphoma (SMZL) malady

Categories: Blood diseases, Rare diseases, Cancer diseases, Immune diseases

Aliases & Classifications for Splenic Marginal Zone Lymphoma

Aliases & Descriptions for Splenic Marginal Zone Lymphoma:

Name: Splenic Marginal Zone Lymphoma 38 12 56 14
Splenic Marginal Zone B-Cell Lymphoma 69
Smzl 56

Characteristics:

Orphanet epidemiological data:

56
splenic marginal zone lymphoma
Age of onset: Adult;

Classifications:



External Ids:

Disease Ontology 12 DOID:0050750
Orphanet 56 ORPHA86854
ICD10 via Orphanet 34 C83.0

Summaries for Splenic Marginal Zone Lymphoma

Disease Ontology : 12 A marginal zone B-cell lymphocyte located in the spleen comprised of B-cells in place of white pulp.

MalaCards based summary : Splenic Marginal Zone Lymphoma, also known as splenic marginal zone b-cell lymphoma, is related to systemic mastocytosis and lymphoma. An important gene associated with Splenic Marginal Zone Lymphoma is NOTCH2 (Notch 2), and among its related pathways/superpathways is NF-kappaB Signaling. The drugs Cyclophosphamide and Lenograstim have been mentioned in the context of this disorder. Affiliated tissues include b cells, spleen and bone, and related phenotypes are hematopoietic system and immune system

Wikipedia : 71 Splenic marginal zone lymphoma (SMZL) is a lymphoma made up of B-cells that replace the normal... more...

Related Diseases for Splenic Marginal Zone Lymphoma

Diseases related to Splenic Marginal Zone Lymphoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 57)
id Related Disease Score Top Affiliating Genes
1 systemic mastocytosis 27.2 AMOTL1 CD5 CDK6 FAT4 GNG11 IRF5
2 lymphoma 11.0
3 hepatitis 10.3
4 b-cell lymphomas 10.3
5 hepatitis c 10.2
6 hepatitis c virus 10.2
7 macroglobulinemia 10.2
8 hemolytic anemia 10.2
9 parotitis 10.2 CD5 MALT1
10 paramyloidosis 10.2 CD5 PAX5
11 autoimmune hemolytic anemia 10.1
12 uterine ligament endometrioid adenocarcinoma 10.1 CD5 PAX5
13 degenerative myopia 10.1 CD5 PAX5
14 basal ganglia disease 10.1 CD5 MALT1 PAX5
15 ectodermal dysplasia 10.1 CD5 MALT1 PAX5
16 mantle cell lymphoma 10.1
17 hodgkin lymphoma 10.1
18 childhood brain stem glioma 10.1 CD5 PAX5
19 bladder disease 10.1 CD5 MALT1 PAX5
20 leukemia 10.0
21 hairy cell leukemia 10.0
22 paraplegia 10.0
23 thrombosis 10.0
24 glomerulonephritis 10.0
25 hepatitis b 10.0
26 angiosarcoma 10.0 ITGAE PAX5
27 ovarian clear cell malignant adenofibroma 9.9 CD5 CDK6
28 splenic disease 9.8
29 splenomegaly 9.8
30 paraneoplastic syndromes 9.8
31 myelofibrosis 9.8
32 membranoproliferative glomerulonephritis 9.8
33 spasticity 9.8
34 neutropenia 9.8
35 adenocarcinoma 9.8
36 hiv-1 9.8
37 cerebritis 9.8
38 hepatocellular carcinoma 9.8
39 heavy chain disease 9.8
40 hypersplenism 9.8
41 gamma heavy chain disease 9.8
42 burkitt lymphoma 9.8
43 polycythemia 9.8
44 multiple myeloma 9.8
45 portal hypertension 9.8
46 evans' syndrome 9.8
47 pure red-cell aplasia 9.8
48 leishmaniasis 9.8
49 diffuse large b-cell lymphoma 9.8
50 interstitial cystitis 9.8

Graphical network of the top 20 diseases related to Splenic Marginal Zone Lymphoma:



Diseases related to Splenic Marginal Zone Lymphoma

Symptoms & Phenotypes for Splenic Marginal Zone Lymphoma

MGI Mouse Phenotypes related to Splenic Marginal Zone Lymphoma:

44
id Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 9.65 TRRAP CD5 CDK6 IRF5 ITGAE KLF2
2 immune system MP:0005387 9.28 CD5 CDK6 IRF5 ITGAE KLF2 MALT1

Drugs & Therapeutics for Splenic Marginal Zone Lymphoma

Drugs for Splenic Marginal Zone Lymphoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 427)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Cyclophosphamide Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 50-18-0, 6055-19-2 2907
2
Lenograstim Approved Phase 4,Phase 3,Phase 2,Phase 1 135968-09-1
3
Thiotepa Approved Phase 4,Phase 2,Phase 3 52-24-4 5453
4 Alkylating Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
5 Antilymphocyte Serum Phase 4,Phase 2,Phase 3,Phase 1
6 Antineoplastic Agents, Alkylating Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
7 Antirheumatic Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
8 Immunosuppressive Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
9
Chlorambucil Approved Phase 3 305-03-3 2708
10
Dexamethasone Approved, Investigational, Vet_approved Phase 3,Phase 2 50-02-2 5743
11
Idarubicin Approved Phase 3 58957-92-9 42890
12
Doxorubicin Approved, Investigational Phase 3,Phase 1,Phase 2 23214-92-8 31703
13
Prednisone Approved, Vet_approved Phase 3,Phase 2,Phase 1 53-03-2 5865
14
rituximab Approved Phase 3,Phase 1,Phase 2 174722-31-7 10201696
15
Vincristine Approved, Investigational Phase 3,Phase 2,Phase 1 2068-78-2, 57-22-7 5978
16
Fludarabine Approved Phase 3,Phase 2,Phase 1 21679-14-1, 75607-67-9 30751
17
Vidarabine Approved Phase 3,Phase 1,Phase 2 24356-66-9 32326 21704
18
Busulfan Approved, Investigational Phase 3,Phase 2,Phase 1,Early Phase 1 55-98-1 2478
19
Melphalan Approved Phase 3,Phase 2,Phase 1 148-82-3 4053 460612
20
Iron Approved Phase 3,Phase 1,Phase 2 7439-89-6 23925
21
Cefepime Approved Phase 3,Phase 1 88040-23-7 5479537
22
Levofloxacin Approved, Investigational Phase 3 100986-85-4 149096
23
Ofloxacin Approved Phase 3 82419-36-1 4583
24
Amoxicillin Approved, Vet_approved Phase 3 26787-78-0 33613 2171
25
Ciprofloxacin Approved, Investigational Phase 3 85721-33-1 2764
26
Ketamine Approved, Vet_approved Phase 3 6740-88-1 3821
27
Cyclosporine Approved, Investigational, Vet_approved Phase 3,Phase 2,Phase 1 79217-60-0, 59865-13-3 5284373 6435893
28
Miconazole Approved, Investigational, Vet_approved Phase 3,Phase 2,Phase 1 22916-47-8 4189
29
Carboplatin Approved Phase 2, Phase 3,Phase 1 41575-94-4 10339178 498142 38904
30
Etoposide Approved Phase 2, Phase 3,Phase 1,Early Phase 1 33419-42-0 36462
31
Mycophenolate mofetil Approved, Investigational Phase 3,Phase 2,Phase 1 128794-94-5 5281078
32
Mycophenolic acid Approved Phase 3,Phase 2,Phase 1 24280-93-1 446541
33
Aldesleukin Approved Phase 3,Phase 1,Phase 2 85898-30-2, 110942-02-4
34
Piperacillin Approved Phase 3 66258-76-2 43672
35
Tazobactam Approved Phase 3 89786-04-9 123630
36
Vancomycin Approved Phase 3 1404-90-6 441141 14969
37
Dalteparin Approved Phase 3 9041-08-1
38
Heparin Approved, Investigational Phase 3 9005-49-6 772 46507594
39
Darbepoetin alfa Approved, Investigational Phase 3,Phase 2 11096-26-7, 209810-58-2
40
Dextromethorphan Approved Phase 3 125-71-3 5360696 5362449
41
Guaifenesin Approved, Vet_approved Phase 3,Phase 2 93-14-1 3516
42
Morphine Approved, Investigational Phase 3 57-27-2 5288826
43
Ondansetron Approved Phase 3,Phase 2,Phase 1 99614-02-5 4595
44
Ephedrine Approved Phase 3 299-42-3 9294
45
Pseudoephedrine Approved Phase 3 90-82-4 7028
46
Amphotericin B Approved, Investigational Phase 3 1397-89-3 14956 5280965
47
Caspofungin Approved Phase 3,Phase 2 179463-17-3, 162808-62-0 468682 2826718
48
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 3 437-38-7 3345
49
Palivizumab Approved, Investigational Phase 3 188039-54-5
50
Ribavirin Approved Phase 3 36791-04-5 37542

Interventional clinical trials:

(show top 50) (show all 495)
id Name Status NCT ID Phase
1 Bone Marrow Transplantation in Treating Patients With Hematologic Cancer Completed NCT00003398 Phase 4
2 Combination Chemotherapy With or Without Interferon Alfa in Treating Patients With Low-Grade Non-Hodgkin's Lymphoma Unknown status NCT00003639 Phase 3
3 Combination Chemotherapy With or Without Rituximab in Treating Older Patients With Non-Hodgkin's Lymphoma Unknown status NCT00052936 Phase 3
4 Interferon Alfa-2b Following Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Recurrent or Refractory Hodgkin's Disease or Non-Hodgkin's Lymphoma Unknown status NCT00003924 Phase 3
5 Radiolabeled Monoclonal Antibody in the Detection and Staging of Patients With Non-Hodgkin's Lymphoma Unknown status NCT00003337 Phase 3
6 Monoclonal Antibodies in Detecting Residual Disease in Patients Who Have Been Treated for Non-Hodgkin's Lymphoma Unknown status NCT00003338 Phase 2, Phase 3
7 Fludarabine and Rituximab With or Without Pixantrone in Treating Patients With Relapsed or Refractory Indolent Non-Hodgkin Lymphoma Unknown status NCT00551239 Phase 3
8 Combination Chemotherapy With or Without Idarubicin and Peripheral Stem Cell Transplantation in Treating Patients With Leukemia or Myelodysplastic Syndrome Unknown status NCT00002989 Phase 3
9 Epoetin Alfa or Epoetin Beta With or Without Iron Infusion in Treating Anemia in Patients With Cancer Unknown status NCT00482716 Phase 3
10 Levofloxacin Compared With Cefepime in Treating Cancer Patients With Fever and Neutropenia Unknown status NCT00020865 Phase 3
11 Early Hospital Discharge or Standard Inpatient Care in Cancer Patients Receiving Antibiotics for Febrile Neutropenia Unknown status NCT00445497 Phase 3
12 Ketamine Hydrochloride and Best Pain Management in Treating Cancer Patients With Neuropathic Pain Unknown status NCT01316744 Phase 3
13 Trial Comparing Chlorambucil to Fludarabine in Patients With Advanced Waldenström Macroglobulinemia Completed NCT00566332 Phase 3
14 Chlorambucil or Fludarabine as First-Line Therapy in Treating Patients With Previously Untreated Waldenström Macroglobulinemia, Splenic Lymphoma, or Lymphoplasmacytic Lymphoma Completed NCT00608374 Phase 3
15 Internet-Based Program With or Without Telephone-Based Problem-Solving Training in Helping Long-Term Survivors of Hematopoietic Stem Cell Transplant Cope With Late Complications Completed NCT00799461 Phase 3
16 Graft-Versus-Host Disease in Treating Patients With Recurrent or Refractory Lymphoma or Hodgkin's Disease Completed NCT00003414 Phase 3
17 Combination Chemotherapy With or Without Rituximab in Treating Patients With Newly Diagnosed Non-Hodgkin's Lymphoma Completed NCT00004112 Phase 3
18 Epoetin Alfa in Treating Anemia in Patients With Lymphoma, Chronic Lymphocytic Leukemia, or Multiple Myeloma and Anemia Caused By Chemotherapy Completed NCT00003341 Phase 3
19 Levofloxacin to Prevent Infection Following Chemotherapy in Treating Patients With Solid Tumors or Lymphoma Completed NCT00005590 Phase 3
20 Prevention of Infection in Patients With Hematologic Cancer and Persistent Fever Caused by a Low White Blood Cell Count Completed NCT00003805 Phase 3
21 Comparison of Nutritional Supplements in Preventing Weight Loss in Patients With Cancer Completed NCT00053053 Phase 3
22 Laboratory-Treated Donor Bone Marrow in Treating Patients Who Are Undergoing a Donor Bone Marrow Transplant for Hematologic Cancer Completed NCT00265837 Phase 3
23 Sibling Donor Peripheral Stem Cell Transplant or Sibling Donor Bone Marrow Transplant in Treating Patients With Hematologic Cancers or Other Diseases Completed NCT00438958 Phase 3
24 Dalteparin to Prevent Complications in Cancer Patients Receiving Chemotherapy Through a Catheter Completed NCT00006083 Phase 3
25 St. John's Wort in Relieving Fatigue in Patients Undergoing Chemotherapy or Hormone Therapy for Cancer Completed NCT00005805 Phase 3
26 Darbepoetin Alfa With or Without Iron in Treating Anemia Caused By Chemotherapy in Patients With Cancer Completed NCT00661999 Phase 3
27 Personalized Information or Basic Information in Helping Patients Make Decisions About Participating in a Clinical Trial Completed NCT00750009 Phase 3
28 American Ginseng in Treating Patients With Fatigue Caused by Cancer Completed NCT00719563 Phase 3
29 Opioid Titration Order Sheet or Standard Care in Treating Patients With Cancer Pain Completed NCT00666211 Phase 3
30 Treatment for Chronic Pain in Patients With Advanced Cancer Completed NCT00003687 Phase 3
31 Ondansetron in Treating Patients With Advanced Cancer and Chronic Nausea and Vomiting Not Caused by Cancer Treatment Completed NCT00006348 Phase 3
32 Cyclosporine Eye Drops in Preventing Graft-Versus-Host Disease of the Eye in Patients Who Have Undergone Donor Stem Cell Transplant for Hematologic Cancer or Bone Marrow Failure Disorder Completed NCT00755040 Phase 3
33 Caspofungin Acetate Compared With Amphotericin B Liposomal in Treating Patients With Persistent Fever and Neutropenia Following Cancer Treatment Completed NCT00008359 Phase 3
34 Liposomal Amphotericin B in Treating Granulocytopenia and Persistent Unexplained Fever in Cancer Patients Completed NCT00003938 Phase 3
35 Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain Completed NCT00538850 Phase 3
36 Ribavirin With or Without Monoclonal Antibody Therapy in Treating Patients Who Develop RSV Pneumonia Following Peripheral Stem Cell Transplantation Completed NCT00014391 Phase 3
37 Itraconazole Compared With Fluconazole to Prevent Infections in Patients Undergoing Peripheral Stem Cell or Bone Marrow Transplantation Completed NCT00003883 Phase 3
38 Music Therapy or Book Discussion in Improving Quality of Life in Young Patients Undergoing Stem Cell Transplant Completed NCT00305851 Phase 3
39 Captopril in Treating Patients Undergoing Bone Marrow or Stem Cell Transplantation Completed NCT00004230 Phase 3
40 Valacyclovir in Preventing Cytomegalovirus Infection in Patients Who Are Undergoing Donor Stem Cell Transplantation Completed NCT00045292 Phase 3
41 Safety and Efficacy Study of BCD-020 in Therapy of Non-Hodgkin's Lymphoma Recruiting NCT01701232 Phase 3
42 Rituximab in Treating Patients With Low Tumor Burden Indolent Non-Hodgkin's Lymphoma Active, not recruiting NCT00075946 Phase 3
43 Combination Chemotherapy and Donor Stem Cell Transplant in Treating Patients With Aplastic Anemia or Hematologic Cancer Active, not recruiting NCT00003816 Phase 2, Phase 3
44 Prevention of Graft-Versus-Host Disease in Patients With Advanced Leukemia or Lymphoma Who Are Eligible for Peripheral Stem Cell Transplantation Terminated NCT00003056 Phase 3
45 Moxifloxacin in Preventing Bacterial Infections in Patients Who Have Undergone Donor Stem Cell Transplant Terminated NCT00324324 Phase 3
46 Mycophenolate Mofetil (MMF) for Treatment of Chronic Graft-versus-host Disease (GVHD) Terminated NCT00089141 Phase 3
47 Brentuximab Vedotin + Rituximab as Frontline Therapy for Pts w/ CD30+ and/or EBV+ Lymphomas Unknown status NCT01805037 Phase 1, Phase 2
48 Lenalidomide as Maintenance Therapy After Combination Chemotherapy With or Without Rituximab and Stem Cell Transplant in Treating Patients With Persistent or Recurrent Non-Hodgkin Lymphoma That is Resistant to Chemotherapy Unknown status NCT01035463 Phase 1, Phase 2
49 Rituximab in Preventing Acute Graft-Versus-Host Disease in Patients Undergoing a Donor Stem Cell Transplant for Hematologic Cancer Unknown status NCT01044745 Phase 2
50 Rituximab and Carmustine, Cytarabine, Etoposide, and Melphalan Followed By Autologous Hematopoietic Stem Cell Transplantation in Treating Patients With B-Cell Non-Hodgkin's Lymphoma Unknown status NCT00080886 Phase 2

Search NIH Clinical Center for Splenic Marginal Zone Lymphoma

Cell-based therapeutics:


LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database
Read about Splenic Marginal Zone Lymphoma cell therapies at LifeMap Discovery.
Stem-cell-based therapeutic approaches for Splenic Marginal Zone Lymphoma:
Hematopoietic stem cells for treatment of hematologic malignancies
Embryonic/Adult Cultured Cells Related to Splenic Marginal Zone Lymphoma:
Bone marrow-derived hematopoietic stem cells

Genetic Tests for Splenic Marginal Zone Lymphoma

Anatomical Context for Splenic Marginal Zone Lymphoma

MalaCards organs/tissues related to Splenic Marginal Zone Lymphoma:

39
B Cells, Spleen, Bone, Bone Marrow, Lymph Node, T Cells, Brain

The Foundational Model of Anatomy Ontology organs/tissues related to Splenic Marginal Zone Lymphoma:

18
The Spleen Comprised Of B-Cells In Place Of White Pulp

Publications for Splenic Marginal Zone Lymphoma

Articles related to Splenic Marginal Zone Lymphoma:

(show top 50) (show all 211)
id Title Authors Year
1
Splenic marginal zone lymphoma: An indolent malignancy leading to the development of neurolymphomatosis. ( 27625159 )
2016
2
Rituximab in a patient with splenic marginal zone lymphoma and acquired angioedema. ( 27017557 )
2016
3
Synchronous rectal adenocarcinoma and splenic marginal zone lymphoma. ( 26966416 )
2016
4
High prevalence of viral hepatitis in a series of splenic marginal zone lymphomas from Romania. ( 27834940 )
2016
5
How to treat splenic marginal zone lymphoma (SMZL) in patients unfit for surgery or more aggressive therapies: experience in 30 cases. ( 27454143 )
2016
6
Splenic marginal zone lymphoma: from genetics to management. ( 26989207 )
2016
7
Primary splenic marginal zone lymphoma: A case report. ( 27772948 )
2016
8
Murine Models of Splenic Marginal Zone Lymphoma: A Role for Cav1? ( 28018857 )
2016
9
Splenic marginal zone lymphoma: Prognostic factors, role of watch and wait policy, and other therapeutic approaches in the rituximab era. ( 27030961 )
2016
10
High prevalence of splenic marginal zone lymphoma among patients with acquired C1 inhibtor deficiency. ( 26728240 )
2016
11
No evidence of splenic disease in patients with splenic marginal zone lymphoma undergoing splenectomy for autoimmune hemolytic anemia after monotherapy with rituximab. ( 27082039 )
2016
12
Paraneoplastic Syndrome in Splenic Marginal Zone Lymphoma: A Rare Phenomenon of Paraplegia as an Atypical Presenting Manifestation. ( 27293921 )
2016
13
An Immunogenetic Signature of Ongoing Antigen Interactions in Splenic Marginal Zone Lymphoma Expressing IGHV1-2*04 Receptors. ( 26647217 )
2016
14
NF-I_B deregulation in splenic marginal zone lymphoma. ( 27503810 )
2016
15
Toll-like receptor stimulation in splenic marginal zone lymphoma can modulate cell signaling, activation and proliferation. ( 26294727 )
2015
16
Successful Treatment of Leukemic Mature B-Cell Lymphoid Neoplasm with Similar Features to Splenic Marginal Zone Lymphoma Possessing Aberrant Myeloid Markers. ( 26558117 )
2015
17
Splenic Marginal Zone Lymphoma in the Setting of Noncirrhotic Portal Hypertension. ( 26904707 )
2015
18
R-COMP as a first-line treatment for Splenic Marginal Zone Lymphoma. A Fondazione Italiana Linfomi phase II study. ( 25791121 )
2015
19
Polymyalgia rheumatica in a patient with splenic marginal zone lymphoma - a case report. ( 25815618 )
2015
20
Whole exome sequencing of microdissected splenic marginal zone lymphoma: a study to discover novel tumor-specific mutations. ( 26498442 )
2015
21
Tissue proteomics of splenic marginal zone lymphoma. ( 25873066 )
2015
22
Outcomes in splenic marginal zone lymphoma: analysis of 107 patients treated in British Columbia. ( 25854936 )
2015
23
DNA methylation profiling identifies two splenic marginal zone lymphoma subgroups with different clinical and genetic features. ( 25612624 )
2015
24
BRAF V600E and MAP2K1 mutations in hairy cell leukemia and splenic marginal zone lymphoma cases. ( 25729732 )
2015
25
Remission of splenic marginal zone lymphoma in a patient treated for hepatitis B: a case of HBV-associated lymphoma. ( 25977147 )
2015
26
Peri-operative complications and hematologic improvement after first-line splenectomy for splenic marginal zone lymphoma. ( 26373930 )
2015
27
Genetics and Prognostication in Splenic Marginal Zone Lymphoma: Revelations from Deep Sequencing. ( 25779943 )
2015
28
Success of interferon I+ therapy in a patient with hepatitis C virus-negative splenic marginal zone lymphoma associated with polycythemia vera. ( 25641434 )
2015
29
Splenic marginal zone lymphoma in an Asian small-clawed otter (Aonyx cinerea). ( 25314852 )
2014
30
KLF2 mutation is the most frequent somatic change in splenic marginal zone lymphoma and identifies a subset with distinct genotype. ( 25428260 )
2014
31
Bone marrow stroma CD40 expression correlates with inflammatory mast cell infiltration and disease progression in splenic marginal zone lymphoma. ( 24452203 )
2014
32
Rapid clearance of HCV-related Splenic Marginal Zone Lymphoma under an Interferon-free, NS3/NS4A inhibitor-based treatment. A case report. ( 25285757 )
2014
33
Rare Presentation of Secondary Cutaneous Involvement by Splenic Marginal Zone Lymphoma: Report of a Case and Review of the Literature. ( 25238446 )
2014
34
Pediatric Presentation of Splenic Marginal Zone Lymphoma on FDG PET/CT Scan. ( 23640226 )
2014
35
Splenic marginal-zone lymphoma: ontogeny and genetics. ( 24798744 )
2014
36
Splenic Marginal Zone Lymphoma and Concurrent Membranoproliferative Glomerulonephritis With IgMKappa Deposits in a HCV-Seropositive Patient. ( 25695019 )
2014
37
The KrA1ppel-like factor 2 transcription factor gene is recurrently mutated in splenic marginal zone lymphoma. ( 25283840 )
2014
38
Splenic marginal zone lymphoma involving the breast: lessons in patient-centered care. ( 24521384 )
2014
39
Lupus anticoagulant and thrombosis in splenic marginal zone lymphoma. ( 25201005 )
2014
40
Validation of the simplified prognostic score for splenic marginal zone lymphoma of the Splenic Marginal Zone Lymphoma Working Group. ( 24576167 )
2014
41
Interference from lupus anticoagulant on von Willebrand factor measurement in splenic marginal zone lymphoma: a case report. ( 25485787 )
2014
42
A restricted IGHV gene repertoire in splenic marginal zone lymphoma is associated with autoimmune disorders. ( 24997147 )
2014
43
Treatment of splenic marginal zone lymphoma with rituximab monotherapy: progress report and comparison with splenectomy. ( 23345547 )
2013
44
Membranous glomerulonephritis associated with splenic marginal zone lymphoma mimicking multiple myeloma. ( 23725648 )
2013
45
Treatment of splenic marginal zone lymphoma: should splenectomy be abandoned? ( 24050506 )
2013
46
Whole-exome sequencing in splenic marginal zone lymphoma reveals mutations in genes involved in marginal zone differentiation. ( 24296945 )
2013
47
Laparoscopic splenectomy for treatment of splenic marginal zone lymphoma. ( 23840125 )
2013
48
Platelet satellitism and dual surface immunoglobulin light-chain expression in circulating splenic marginal zone lymphoma cells. ( 21889383 )
2013
49
Comparative outcomes of rituximab-based systemic therapy and splenectomy in splenic marginal zone lymphoma. ( 24057925 )
2013
50
Long-term follow-up analysis of 100 patients with splenic marginal zone lymphoma treated with splenectomy as first-line treatment. ( 24206091 )
2013

Variations for Splenic Marginal Zone Lymphoma

Cosmic variations for Splenic Marginal Zone Lymphoma:

9 (show all 44)
id Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Mutation CDS Mutation AA Conf
1 COSM4944029 TRAF3 haematopoietic and lymphoid tissue,spleen,lymphoid neoplasm,marginal zone lymphoma c.193C>T p.Q65* 6
2 COSM44215 TP53 haematopoietic and lymphoid tissue,spleen,lymphoid neoplasm,marginal zone lymphoma c.533A>C p.H178P 6
3 COSM10660 TP53 haematopoietic and lymphoid tissue,spleen,lymphoid neoplasm,marginal zone lymphoma c.818G>A p.R273H 6
4 COSM10701 TP53 haematopoietic and lymphoid tissue,spleen,lymphoid neoplasm,marginal zone lymphoma c.824G>T p.C275F 6
5 COSM43949 TP53 haematopoietic and lymphoid tissue,spleen,lymphoid neoplasm,marginal zone lymphoma c.401T>G p.F134C 6
6 COSM11073 TP53 haematopoietic and lymphoid tissue,spleen,lymphoid neoplasm,marginal zone lymphoma c.1024C>T p.R342* 6
7 COSM43842 TP53 haematopoietic and lymphoid tissue,spleen,lymphoid neoplasm,marginal zone lymphoma c.770T>C p.L257P 6
8 COSM43909 TP53 haematopoietic and lymphoid tissue,spleen,lymphoid neoplasm,marginal zone lymphoma c.817C>A p.R273S 6
9 COSM44216 TP53 haematopoietic and lymphoid tissue,spleen,lymphoid neoplasm,marginal zone lymphoma c.487T>G p.Y163D 6
10 COSM43606 TP53 haematopoietic and lymphoid tissue,spleen,lymphoid neoplasm,marginal zone lymphoma c.734G>A p.G245D 6
11 COSM11374 TP53 haematopoietic and lymphoid tissue,spleen,lymphoid neoplasm,marginal zone lymphoma c.752T>A p.I251N 6
12 COSM133688 TNFAIP3 haematopoietic and lymphoid tissue,spleen,lymphoid neoplasm,marginal zone lymphoma c.553G>T p.G185* 6
13 COSM4944038 TBL1XR1 haematopoietic and lymphoid tissue,spleen,lymphoid neoplasm,marginal zone lymphoma c.1058A>G p.N353S 6
14 COSM4944027 SPEN haematopoietic and lymphoid tissue,spleen,lymphoid neoplasm,marginal zone lymphoma c.5428C>G p.P1810A 6
15 COSM3802617 SPEN haematopoietic and lymphoid tissue,spleen,lymphoid neoplasm,marginal zone lymphoma c.2170C>T p.R724* 6
16 COSM4944041 SIN3A haematopoietic and lymphoid tissue,spleen,lymphoid neoplasm,marginal zone lymphoma c.1232C>T p.P411L 6
17 COSM4944040 SIN3A haematopoietic and lymphoid tissue,spleen,lymphoid neoplasm,marginal zone lymphoma c.430T>C p.Y144H 6
18 COSM1168004 NOTCH2 haematopoietic and lymphoid tissue,spleen,lymphoid neoplasm,marginal zone lymphoma c.7231G>T p.E2411* 6
19 COSM329077 NOTCH2 haematopoietic and lymphoid tissue,spleen,lymphoid neoplasm,marginal zone lymphoma c.6973C>T p.Q2325* 6
20 COSM36210 NOTCH2 haematopoietic and lymphoid tissue,spleen,lymphoid neoplasm,marginal zone lymphoma c.7198C>T p.R2400* 6
21 COSM876755 NOTCH2 haematopoietic and lymphoid tissue,spleen,lymphoid neoplasm,marginal zone lymphoma c.7163C>G p.S2388* 6
22 COSM674043 NOTCH2 haematopoietic and lymphoid tissue,spleen,lymphoid neoplasm,marginal zone lymphoma c.7078C>T p.Q2360* 6
23 COSM329075 NOTCH2 haematopoietic and lymphoid tissue,spleen,lymphoid neoplasm,marginal zone lymphoma c.7072A>G p.M2358V 6
24 COSM329072 NOTCH2 haematopoietic and lymphoid tissue,spleen,lymphoid neoplasm,marginal zone lymphoma c.6853C>T p.Q2285* 6
25 COSM329069 NOTCH2 haematopoietic and lymphoid tissue,spleen,lymphoid neoplasm,marginal zone lymphoma c.6304A>T p.K2102* 6
26 COSM36073 NOTCH2 haematopoietic and lymphoid tissue,spleen,lymphoid neoplasm,marginal zone lymphoma c.7021C>T p.Q2341* 6
27 COSM957497 NOTCH2 haematopoietic and lymphoid tissue,spleen,lymphoid neoplasm,marginal zone lymphoma c.7030G>T p.E2344* 6
28 COSM85940 MYD88 haematopoietic and lymphoid tissue,spleen,lymphoid neoplasm,marginal zone lymphoma c.794T>C p.L265P 6
29 COSM4944023 IKBKB haematopoietic and lymphoid tissue,spleen,lymphoid neoplasm,marginal zone lymphoma c.511A>G p.K171E 6
30 COSM4944024 IKBKB haematopoietic and lymphoid tissue,spleen,lymphoid neoplasm,marginal zone lymphoma c.512A>C p.K171T 6
31 COSM4944042 FAT4 haematopoietic and lymphoid tissue,spleen,lymphoid neoplasm,marginal zone lymphoma c.739C>A p.P247T 6
32 COSM220734 CD79B haematopoietic and lymphoid tissue,spleen,lymphoid neoplasm,marginal zone lymphoma c.586T>C p.Y196H 6
33 COSM41660 CARD11 haematopoietic and lymphoid tissue,spleen,lymphoid neoplasm,marginal zone lymphoma c.1070A>T p.D357V 6
34 COSM85864 CARD11 haematopoietic and lymphoid tissue,spleen,lymphoid neoplasm,marginal zone lymphoma c.1202A>T p.D401V 6
35 COSM133703 CARD11 haematopoietic and lymphoid tissue,spleen,lymphoid neoplasm,marginal zone lymphoma c.746A>C p.Q249P 6
36 COSM674177 CARD11 haematopoietic and lymphoid tissue,spleen,lymphoid neoplasm,marginal zone lymphoma c.583G>C p.V195L 6
37 COSM30440 CARD11 haematopoietic and lymphoid tissue,spleen,lymphoid neoplasm,marginal zone lymphoma c.572A>G p.N191S 6
38 COSM133704 CARD11 haematopoietic and lymphoid tissue,spleen,lymphoid neoplasm,marginal zone lymphoma c.770T>C p.I257T 6
39 COSM220934 CARD11 haematopoietic and lymphoid tissue,spleen,lymphoid neoplasm,marginal zone lymphoma c.1201G>A p.D401N 6
40 COSM1735759 BIRC3 haematopoietic and lymphoid tissue,spleen,lymphoid neoplasm,marginal zone lymphoma c.1636G>T p.E546* 6
41 COSM1350362 BIRC3 haematopoietic and lymphoid tissue,spleen,lymphoid neoplasm,marginal zone lymphoma c.1690G>T p.E564* 6
42 COSM4944028 BIRC3 haematopoietic and lymphoid tissue,spleen,lymphoid neoplasm,marginal zone lymphoma c.1716T>A p.C572* 6
43 COSM1735760 BIRC3 haematopoietic and lymphoid tissue,spleen,lymphoid neoplasm,marginal zone lymphoma c.956G>A p.C319Y 6
44 COSM674181 ARID1A haematopoietic and lymphoid tissue,spleen,lymphoid neoplasm,marginal zone lymphoma c.5532G>A p.W1844* 6

Copy number variations for Splenic Marginal Zone Lymphoma from CNVD:

7 (show top 50) (show all 56)
id CNVD ID Chromosom Start End Type Gene Symbol CNVD Disease
1 31168 1 25800000 154800000 Duplication Splenic marginal zone lymphoma
2 38774 10 104900000 119100000 Deletion Splenic marginal zone lymphoma
3 56497 11 59700000 61400000 Duplication Splenic marginal zone lymphoma
4 69123 12 53100000 55200000 Gain GLI1 Splenic marginal zone lymphoma
5 78495 13 52200000 109100000 Gain Splenic marginal zone lymphoma
6 86225 14 55800000 78400000 Loss Splenic marginal zone lymphoma
7 91971 15 37900000 47600000 Deletion Splenic marginal zone lymphoma
8 97450 16 10300000 16700000 Gain Splenic marginal zone lymphoma
9 106744 17 1 11200000 Deletion Splenic marginal zone lymphoma
10 106745 17 1 11200000 Deletion Splenic marginal zone lymphoma
11 108750 17 22200000 78774742 Duplication Splenic marginal zone lymphoma
12 119209 18 1 76117153 Duplication Splenic marginal zone lymphoma
13 120285 18 23300000 31000000 Deletion Splenic marginal zone lymphoma
14 134527 2 102400000 159600000 Deletion Splenic marginal zone lymphoma
15 155734 20 57900000 62435964 Duplication Splenic marginal zone lymphoma
16 160287 22 11800000 49691432 Duplication Splenic marginal zone lymphoma
17 166594 3 104400000 107800000 Deletion Splenic marginal zone lymphoma
18 173065 3 189400000 193800000 Duplication Splenic marginal zone lymphoma
19 177287 3 5500000 8700000 Deletion Splenic marginal zone lymphoma
20 178512 3 74200000 83700000 Duplication Splenic marginal zone lymphoma
21 181981 4 131300000 151000000 Deletion Splenic marginal zone lymphoma
22 190152 4 84000000 161500000 Deletion Splenic marginal zone lymphoma
23 190418 4 88200000 94000000 Duplication Splenic marginal zone lymphoma
24 201328 5 68400000 73300000 Duplication Splenic marginal zone lymphoma
25 207408 6 155600000 160900000 Duplication Splenic marginal zone lymphoma
26 209385 6 26100000 45200000 Duplication Splenic marginal zone lymphoma
27 212692 6 40600000 45200000 Duplication Splenic marginal zone lymphoma
28 217433 7 101175494 101390682 Deletion CUX1 Splenic marginal zone lymphoma
29 217434 12 109956211 110272739 Deletion CUX2 Splenic marginal zone lymphoma
30 217435 7 101175494 101390682 Deletion MUC12 Splenic marginal zone lymphoma
31 217436 7 101175494 101390682 Deletion MUC3 Splenic marginal zone lymphoma
32 218058 7 107200000 147500000 Deletion Splenic marginal zone lymphoma
33 219020 7 120900000 123600000 Loss POT1 Splenic marginal zone lymphoma
34 219788 7 130078078 130270796 Deletion AGK Splenic marginal zone lymphoma
35 219789 7 130078078 130270796 Deletion BPGM Splenic marginal zone lymphoma
36 219790 7 130078078 130270796 Deletion CALD1 Splenic marginal zone lymphoma
37 219791 7 130078078 130270796 Deletion CNTNAP2 Splenic marginal zone lymphoma
38 219792 7 130078078 130270796 Deletion FOXP2 Splenic marginal zone lymphoma
39 219793 7 130078078 130270796 Deletion GRM8 Splenic marginal zone lymphoma
40 219794 7 130078078 130270796 Deletion IMMP2L Splenic marginal zone lymphoma
41 219795 7 130078078 130270796 Deletion KEL Splenic marginal zone lymphoma
42 219796 7 130078078 130270796 Deletion MET Splenic marginal zone lymphoma
43 219797 7 130078078 130270796 Deletion MLKN1 Splenic marginal zone lymphoma
44 219798 7 130078078 130270796 Deletion PTN Splenic marginal zone lymphoma
45 219799 7 130078078 130270796 Deletion PTPRZ1 Splenic marginal zone lymphoma
46 219800 7 130078078 130270796 Deletion ST7 Splenic marginal zone lymphoma
47 219801 7 130078078 130270796 Deletion SVOPL Splenic marginal zone lymphoma
48 219802 7 130078078 130270796 Deletion TES Splenic marginal zone lymphoma
49 219803 7 130078078 130270796 Deletion THAP5 Splenic marginal zone lymphoma
50 219804 7 130078078 130270796 Deletion TPK1 Splenic marginal zone lymphoma

Expression for Splenic Marginal Zone Lymphoma

Search GEO for disease gene expression data for Splenic Marginal Zone Lymphoma.

Pathways for Splenic Marginal Zone Lymphoma

Pathways related to Splenic Marginal Zone Lymphoma according to GeneCards Suite gene sharing:

id Super pathways Score Top Affiliating Genes
1 11.42 IRF5 MALT1 PAX5 TRAF3

GO Terms for Splenic Marginal Zone Lymphoma

Biological processes related to Splenic Marginal Zone Lymphoma according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 hippo signaling GO:0035329 9.16 AMOTL1 FAT4
2 Notch signaling pathway GO:0007219 9.13 CDK6 FAT4 NOTCH2
3 lateral ventricle development GO:0021670 8.62 CDK6 PAX5

Molecular functions related to Splenic Marginal Zone Lymphoma according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 protein binding GO:0005515 9.4 AMOTL1 CD5 CDK6 FAT4 GNG11 IRF5

Sources for Splenic Marginal Zone Lymphoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....